Home

Top Picks: Accredited Activities

Naval Daver, MD; Courtney D. DiNardo, MD, MSCE; Eunice S. Wang, MD

Pinkal Desai, MD, MPH, Alexander Perl, MD, Daniel A. Pollyea, MD, and Farhad Ravandi, MD

Harry P. Erba, MD, PhD

VIDEO FAQ: Development of a Novel NGS-Based Assay for MRD in FLT3-ITD AML - M. Levis, MD (4:04) - Posted 01/04
VIDEO: Managing High-Risk and Relapsed/Refractory AML: Where Is Research Headed Next? - A. Fathi, MD (29:28) - Posted 11/28
ENEWSLETTER: Optimizing Treatment in the Older Patient with AML - F. Ravandi, MD - Posted 11/06
VIDEO FAQ: Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial - E. Stein, MD (4:09) - Posted 01/04
FAQ: An overview of the recently approved combination of venetoclax with azacitidine or decitabine or low-dose cytarabine - H. Erba, MD - Posted 12/13
Additional activities...

PODCAST: What are the most important prognostic factors to consider in AML? - P. Desai, MD (2:19) - Posted 12/05
VIDEO FAQ: How likely is it for patients with MDS to transform to AML? - J. Park, MD (3:33) - Posted 11/07
VIDEO FAQ: What are the practical issues in FLT3 testing as it relates to PCR vs. NGS? - A. Perl, MD (3:18) - Posted 10/10
VIDEO FAQ: What are the latest guidelines for molecular testing in AML? - J. Patel, MD (1:56) - Posted 07/24
Additional activities...